{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "LYEL", "name": "Lyell Immunopharma, Inc.", "url": "https://frontierpicks.com/dossiers/LYEL/", "json_url": "https://frontierpicks.com/dossiers/LYEL.json", "status": "WATCHLIST", "current_conviction": "MEDIUM", "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Lyell Immunopharma's ronde-cel is posting response rates strong enough to support a planned 2027 approval filing, with a 91% response rate in 44 pivotal-trial patients and new funding into 2028. The December 2026 ASH presentations are the next test, and pivotal results due in mid-2027 settle the case.", "invalidation_trigger": "A daily close below $10.77, the price institutional investors paid in the November 2026 private placement. A clinical hold on ronde-cel, or a slip in the mid-2027 pivotal readout, would also end the case.", "catalyst_date": "2026-12-04", "pick": { "id": "P-2026-11-06-LYEL", "conviction": "MEDIUM", "status": "open", "opened": "2026-11-06", "open_close": 14.86, "kill_level": 10.77, "kill_basis": "daily", "horizon_end": "2027-02-09", "last_date": "2026-11-06", "last_close": 14.86, "return_pct": 0, "spy_return_pct": 0, "excess_pp": 0, "kill_distance_pct": 37.975858867223764, "closed": null, "close_reason": null, "outcome": null, "scoreboard": "https://frontierpicks.com/track-record/" }, "themes": [ "oncology-immunology" ], "tags": [], "sources": [], "notes": [ "Lyell Immunopharma has no approved product; ronde-cel remains investigational and the company reported Q3 2026 revenue of $3 thousand.", "Clinical figures cited from the ongoing PiNACLE and Phase 1/2 trials are company-reported interim results that can change with longer follow-up." ], "source_links": [ { "title": "Lyell Immunopharma, Inc. - Form 8-K - FY2026", "url": "https://www.sec.gov/Archives/edgar/data/0001806952/000162828026070161/lyel-20261104x8kexx991.htm", "date": "2026-11-04" }, { "title": "Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory…", "url": "https://ir.lyell.com/news-releases/news-release-details/lyell-immunopharma-present-positive-updated-ronde-cel-data-more", "date": null }, { "title": "Lyell Immunopharma, Inc. - Form 8-K - FY2026", "url": "https://www.sec.gov/Archives/edgar/data/0001806952/000119312526446317/d158628d8k.htm", "date": null }, { "title": "Lyell Immunopharma Shares Surge 44% On $80 Mln Private Placement And Positive Ronde-Cel Data", "url": "https://rttnews.com/3709693/lyell-immunopharma-shares-surge-44-on-80-mln-private-placement-and-positive-ronde-cel-data.aspx", "date": null }, { "title": "Lyell Immunopharma (LYEL) Raises $80M in Private Placement to Bolster CAR T-Cell Therapy Pipeline", "url": "https://www.gurufocus.com/news/9170160/lyell-immunopharma-lyel-raises-80m-in-private-placement-to-bolster-car-tcell-therapy-pipeline", "date": null }, { "title": "Lyell Immunopharma, Inc. (LYEL)", "url": "https://stockanalysis.com/stocks/lyel/forecast", "date": null } ], "body_markdown": "## Current Thesis\nLyell Immunopharma's lymphoma cell therapy, ronde-cel, is posting response rates strong enough to support a planned 2027 approval filing, and a new $80.0 million financing is expected to fund the company past that filing. The December 2026 hematology meeting is the next test, and pivotal results due in mid-2027 settle it.\n\nRonde-cel (rondecabtagene autoleucel) is a chimeric antigen receptor T-cell (CAR T) therapy for large B-cell lymphoma (LBCL) that has come back or stopped responding to earlier treatment. In the company's 2026-11-04 release, 91% of 44 evaluable patients in the pivotal PiNACLE trial responded and 77% had a complete response.\n\nThe narrative is accelerating: the 2026-11-04 clinical update, an oral presentation slot at the American Society of Hematology (ASH) meeting and a financing with new investors all arrived together, and RTTNews reported a 44% jump in the shares that day. The shares closed at $15.00 on 2026-11-05. Pivotal results fall outside the next three months, so the nearer case rests on the ASH presentations and on PiNACLE enrollment finishing by year-end.\n\n## Bull Case\n- **Pivotal response rates are high.** Among 44 evaluable PiNACLE patients treated after two or more prior therapies, the overall response rate was 91% and the complete response rate 77%, per the company's 2026-11-04 release. Median duration of complete response and median progression-free survival were not reached.\n- **Severe side effects look limited.** The same release reports no Grade 3 or higher cytokine release syndrome. Grade 3 or higher neurotoxicity occurred in 9% of those patients.\n- **Earlier-line results match the pivotal trial.** In 37 evaluable second-line patients from the Phase 1/2 trial, the overall response rate was 95% and the complete response rate 76%, per the company's 2026-11-04 ASH release. That supports the randomized Phase 3 PiNACLE-H2H trial against axi-cel or liso-cel.\n- **Funding now extends into 2028.** A 2026-11-03 purchase agreement sold 7,428,040 shares at $10.77 for about $80.0 million gross, per the company's 8-K. Management expects cash to last into 2028, beyond the filing planned for the second half of 2027.\n- **Published targets sit far above the price.** Needham reiterated a Buy rating and a $44.00 target on 2026-11-03. StockAnalysis showed a $37.88 consensus target from 8 analysts on 2026-11-06.\n\n## Bear Case\n- **The decisive readout is months away.** The company expects pivotal results in mid-2027 and a biologics license application in the second half of 2027, per its 2026-11-04 release. Ronde-cel has no approval, and Q3 2026 revenue was $3 thousand.\n- **Complete responses fade over time.** Among complete responders in PiNACLE, the estimated share still in complete response fell from 92% at six months to 75% at 12 months. In the second-line cohort it fell from 92% to 67%, and these are estimates from ongoing trials.\n- **New shares can reach the market.** The placement agreement requires a resale registration statement within 30 days of closing, per the 8-K.\n- **Spending is rising.** Research and development expense rose to $40.9 million in Q3 2026 from $28.2 million a year earlier, and the net loss widened to $45.5 million from $38.8 million. Cash and securities fell to $194.0 million on 2026-09-30 from $247.2 million on 2025-12-31, before the placement.\n- **The Phase 3 comparators are established drugs.** PiNACLE-H2H tests ronde-cel against marketed therapies on event-free survival and was still enrolling on 2026-11-04. Strong single-arm results do not settle that comparison.\n\n## Setup & Price Structure\nThe shares closed at $15.00 on 2026-11-05 in adjusted daily closes, 61.1% below the 52-week high of $38.60 and up 4.7% over three months. The large one-day move therefore returned the shares only slightly above their level of three months ago.\n\nThe clearest crowding sign is the 14-day relative strength index of 85.8 on 2026-11-05, a very stretched reading after the 2026-11-04 jump. Reports of that day's move differ, with RTTNews citing 44% and GuruFocus 35%. The other observable pressure is share issuance: the $10.77 placement price is the most visible reference level below the market.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-12-04, est.:** Deadline for filing the resale registration statement, 30 days after the placement's expected closing on or about 2026-11-04.\n- **2026-12-12 to 2026-12-15 (just beyond 30 days):** ASH meeting, with PiNACLE as Oral Abstract 1028 and the second-line cohort as Poster Abstract 2402. The case turns on this update.\n- **By 2026-12-31:** The company expects PiNACLE enrollment to be complete.\n- **Mid-2027:** Pivotal PiNACLE results, followed by the planned application in the second half of 2027.\n\n## What Would Change Our Mind\nThe case breaks if ronde-cel's efficacy or safety weakens as follow-up grows. Clear signs would be a PiNACLE complete response rate well below 77%, a 12-month continued complete response estimate well below 75%, or a rise in Grade 3 or higher neurotoxicity above 9%.\n\nA clinical hold from the Food and Drug Administration would also end it. So would enrollment running past year-end 2026, or a slip in the mid-2027 readout or second-half 2027 filing. A further equity raise before those results would undercut the claim that funding is settled into 2028.\n\nOn price, a daily close below $10.77 would take the shares under what institutional investors paid in the placement and would show the market rejecting the 2026-11-04 news.\n\n## Correlation Notes\nThe 2026-11-04 move was tied to Lyell's own clinical update and financing, per RTTNews, so the case depends more on company results than on sector direction. Attention on the Oncology & immunology group, which includes Xencor, Genmab, Replimune and Halozyme, has alternated between heating and cooling since July and was maturing in early November on this site's weekly theme tracking. That raises the bar for the shares without changing the clinical reading.\n\nThe closer read-across comes from CAR T competitors, because axi-cel and liso-cel are the comparator therapies in PiNACLE-H2H. New long-term results or wider use of those two drugs would raise the standard ronde-cel has to meet.", "first_seen": "2026-11-06", "last_analyzed": "2026-11-06T12:17:54+00:00", "last_synthesized": "2026-11-06", "last_update_source": "research_universe", "license": "Content © FrontierPicks. Cite the canonical URL." }